b
r
c
r
c
l
e
n
f
develop
effect
cancer
therapeut
strategi
reli
abil
interfer
cellular
process
dysregul
tumor
given
essenti
role
ubiquitin
proteasom
system
up
regul
myriad
cellular
process
surpris
malfunct
up
compon
implic
numer
human
diseas
includ
mani
type
cancer
clinic
success
proteasom
inhibitor
treat
multipl
myeloma
stimul
enthusiasm
target
up
protein
pharmacolog
intervent
cancer
treatment
particularli
precis
medicin
era
unfortun
despit
tremend
effort
pauciti
potent
select
up
inhibitor
sever
hamper
attempt
exploit
up
therapeut
benefit
tackl
problem
mani
group
work
technolog
advanc
rapidli
effect
screen
potent
specif
up
modul
intracellular
probe
earlyphas
therapeut
agent
review
sever
emerg
technolog
develop
chemicaland
proteinbas
molecul
manipul
up
enzymat
activ
aim
provid
overview
strategi
avail
target
ubiquitin
cancer
therapi
ever
sinc
discoveri
ubiquitin
ub
four
decad
ago
ciehanov
hod
hershko
small
protein
link
multipl
cellular
process
includ
cell
prolifer
develop
immun
respons
numer
human
diseas
includ
cancer
calistri
munegato
carli
parolin
palu
dantuma
bott
senft
qi
ronai
zinngreb
montinaro
peltzer
walczak
inde
protein
ubiquitin
process
attach
ub
polyub
chain
cellular
substrat
integr
essenti
part
cell
machineri
serv
modifi
regul
degrad
protein
fig
swatek
komand
ubiquitin
initi
activ
ub
ub
activ
enzym
adenyl
ub
cterminu
use
catalyt
cystein
residu
result
thioester
bond
anoth
thioester
reaction
requir
transfer
ub
onto
ub
conjug
enzym
ubcharg
enzym
recruit
ub
ligas
respons
transfer
ub
state
substrat
protein
date
two
ubspecif
activ
enzym
identifi
human
groettrup
pelzer
schmidtk
hofmann
mchugh
et
al
schulman
harper
found
human
morreal
walden
mulder
et
al
human
also
harbour
approxim
ub
ligas
classifi
homolog
protein
carboxi
terminu
hect
famili
realli
interest
new
gene
ring
famili
ubox
famili
morreal
walden
mulder
harari
simon
zhang
sidhu
ligas
bind
enzym
thioesterifi
ub
mediat
substrat
ubiquitin
differ
catalyt
mechan
hect
ligas
form
intermedi
thioester
bond
ub
activ
site
cystein
residu
transfer
substrat
contrast
lack
catalyt
cystein
ring
ubox
ligas
facilit
ub
transfer
alloster
mechan
chen
et
al
ozkan
yu
deisenhof
rotin
kumar
zheng
shabek
singl
multipl
monoubiquitin
polyubiquitin
nterminu
lysin
residu
ub
possibl
modif
protein
substrat
determin
fate
protein
calistri
et
al
ubiquitin
residu
ub
link
endoplasm
reticulumassoci
protein
degrad
lock
toth
petroski
ubiquitin
associ
protein
modif
nucifora
jr
et
al
ubiquitin
well
studi
role
proteasom
degrad
cellular
substrat
calistri
et
al
ubiquitin
result
protein
recruit
autophagi
degrad
lysosom
pathway
erpapazogl
walker
haguenauertsapi
end
spectrum
process
ubiquitin
revers
deubiquitin
enzym
known
deubiquitinas
dub
zhang
sidhu
human
encod
seven
differ
structur
famili
dub
compris
almost
protein
total
hermann
et
al
wertz
wang
ubspecif
proteas
usp
repres
largest
best
studi
famili
close
usp
current
describ
yuan
et
al
less
research
report
famili
next
best
studi
ovarian
fig
drug
target
ubiquitin
proteasom
system
schemat
represent
ubiquitin
pathway
ubiquitin
involv
three
step
first
activ
ubiquitin
ub
atp
form
thioester
bond
next
activ
ub
conjug
enzym
via
transthiol
reaction
final
ring
ubox
ligas
recruit
enzym
substrat
facilit
transfer
ub
substrat
alloster
mechan
wherea
hect
ligas
directli
ubiquitin
substrat
follow
transfer
ub
hect
ligas
activ
site
chen
et
al
zhang
sidhu
diagram
also
illustr
drug
develop
target
current
market
green
dot
clinic
trial
blue
dot
still
test
industri
academia
red
dot
pimozid
current
use
clinic
cancer
therapi
previous
known
tong
et
al
identifi
within
smallmolecul
screen
inhibitor
ub
conjug
enzym
pulvino
et
al
b
ub
conjug
lysin
monoubiquitin
multipl
time
multiubiquitin
singl
unit
chain
polyubiquitin
monoubiquitin
multiubiquitin
process
link
protein
function
modif
receptor
endocytosi
nuclear
export
transcript
histon
regul
polyubiquitin
shown
lead
proteasom
degrad
part
up
polyubiquitin
implic
lysosom
pathway
protein
recruit
membran
intern
endosom
uptak
autophagi
deubiquitin
may
also
occur
swatek
komand
tumor
ub
proteas
otu
follow
domain
jamm
metalloenzym
proteas
ub
ctermin
hydrolas
uch
josephin
domain
proteas
yuan
et
al
target
ubiquitin
pathway
attract
avenu
anticanc
drug
develop
especi
approv
success
proteasom
inhibitor
drug
bortezomib
carfilzomib
fig
treatment
relaps
refractori
multipl
myeloma
richardson
et
al
richardson
et
al
propel
mani
studi
clinic
trial
find
new
therapeut
target
individu
compon
ubiquitin
pathway
treatment
cancer
aim
provid
better
therapeut
fewer
side
effect
tabl
chen
frezza
schmitt
kanwar
dou
iida
et
al
yazbeck
et
al
anoth
import
aspect
consid
select
kill
cancer
cell
rather
normal
cell
target
ubiquitin
ubiquitin
upregul
due
errorpron
natur
cancer
cell
tissu
gallo
ko
donoghu
ge
et
al
inde
bortezomib
carfilzomib
higher
activ
malign
cell
normal
cell
tissu
berker
et
al
codonyservat
et
al
parlati
et
al
inhibitor
up
compon
also
shown
uniqu
target
cancer
cell
fisku
et
al
li
et
al
pulvino
et
al
tsukamoto
et
al
final
resist
refract
recurr
trait
cancer
inevit
result
turnov
promis
drug
like
bortezomib
due
develop
resist
respons
treatment
hamouda
et
al
consequ
find
new
compound
target
oncogen
pathway
crucial
establish
effect
cancer
therapi
therefor
develop
innov
strategi
valid
target
up
protein
remain
import
aspect
drug
discoveri
cancer
research
dive
recent
advanc
technolog
briefli
describ
earli
stage
drug
discoveri
histor
perspect
two
crucial
type
screen
method
pioneer
develop
targetbas
screen
focu
specif
protein
interest
review
croston
phenotyp
screen
concentr
diseas
state
treatedreview
wagner
targetbas
highthroughput
screen
ht
strategi
drug
discoveri
kick
earli
pereira
william
fig
around
time
research
start
use
phenotyp
screen
genom
manipul
paint
pictur
cellular
replic
normal
state
cell
mainli
yeast
model
organ
fraczek
naseeb
delneri
strynatka
gurrolag
berman
mcmaster
combin
approach
late
result
birth
chemic
genet
led
mani
power
develop
direct
evolut
enzym
phage
display
peptid
antibodi
refin
targetbas
ht
eg
combinatori
chemistri
splitandpool
synthesi
fragmentbas
discoveri
furka
asgedom
diboa
smith
strynatka
et
al
fig
late
begin
use
anim
model
shift
cellbas
screen
minim
number
reagent
requir
allow
output
screen
increas
strynatka
et
al
fig
research
year
also
brought
forth
gener
first
dnaencod
compound
librari
decl
brenner
lerner
kinoshita
nishigaki
fig
within
span
year
highthroughput
technolog
advanc
includ
feat
protein
engin
proteolysistarget
chimera
protac
deriv
ubiquitin
pathway
zhou
bogacki
mcreynold
howley
streamlin
phage
display
approach
includ
ub
variant
ubv
target
proteinprotein
interact
up
brown
et
al
ernst
et
al
ernst
sidhu
gabrielsen
et
al
ordureau
et
al
zhang
et
al
zhang
et
al
zhang
et
al
zhang
sidhu
cellbas
pharmacolog
ht
assay
enhanc
oncolyt
viru
cancercellkil
effici
viral
sensit
screen
bourgeoisdaigneault
et
al
diallo
et
al
fig
less
ten
year
ht
targetbas
phenotyp
approach
pivot
drug
discoveri
yield
new
molecular
entiti
nextgener
drug
test
clinic
trial
respect
swinney
anthoni
instanc
ub
conjug
enzym
inhibitor
discov
phenotyp
targetbas
small
molecul
screen
chen
dexheim
et
al
davydov
et
al
dodg
gavori
et
al
gombodorj
et
al
lee
et
al
odowd
et
al
tong
et
al
yang
et
al
yang
et
al
lebraud
et
al
sakamoto
et
al
sakamoto
et
al
xie
et
al
protein
design
engin
zhang
et
al
tuberculosi
therapeut
darwin
ehrt
gutierrezramo
weich
nathan
fig
tabl
sinc
ubiquitin
pathway
up
target
implic
cancer
drug
develop
extens
review
kar
keskin
fraternali
gursoy
li
et
al
pal
young
donato
shen
schmitt
buac
dou
wertz
wang
zhang
sidhu
focu
address
emerg
trend
applic
rapidli
identifi
modul
protein
within
ubiquitin
pathway
topic
discuss
examin
use
highthroughput
technolog
small
molecul
approach
peptid
mimet
protein
engin
addit
discuss
potenti
applic
technolog
cancer
therapeut
research
research
chemic
space
jenck
stimul
develop
ambiti
targetbas
ht
approach
fig
drugprotein
interact
simplifi
bind
event
probabl
bind
would
increas
size
molecul
jenck
previou
ht
reli
assay
natur
synthet
compound
typic
origin
tediou
timeconsum
reaction
individu
reagent
pereira
william
fig
advent
combinatori
chemistri
mixtur
instead
individu
reagent
began
employ
gener
mani
differ
compound
furka
fig
later
furka
colleagu
introduc
splitandpool
synthesi
furka
et
al
notion
combinatori
chemistri
exploit
includ
separ
ligat
compound
separ
ligat
reaction
increas
number
potenti
combin
fig
estim
total
approxim
million
chemic
compound
global
hann
oprea
number
exceed
millionto
billioncompound
librari
routin
screen
industri
davi
plowright
valeur
goodnow
jr
dumelin
keef
litovchick
et
al
howev
sinc
potenti
druglik
chemic
space
estim
number
still
bare
scratch
surfac
davi
et
al
although
combinatori
chemistri
splitandpool
synthesi
sampl
larger
chemic
space
revolution
way
ht
conduct
targetbas
drug
discoveri
potyrailo
et
al
progress
remain
hamper
signific
bottleneck
includ
expens
set
ht
system
start
reagent
poor
properti
presenc
reactiv
aggreg
molecul
tabl
erlanson
fact
earli
compound
poor
properti
like
high
lipophil
respons
fail
ht
project
keseru
makara
starter
reagent
lack
qualiti
solubl
result
ineffici
downstream
drug
candid
might
impract
clinic
set
keseru
makara
problem
reactiv
molecul
aggreg
also
delay
progress
targetbas
ht
erlanson
reactiv
molecul
small
impur
oxid
protein
condit
use
ht
result
gener
hydrogen
peroxid
inactiv
protein
caus
fals
posit
reactiv
molecul
could
aris
possibl
combin
splitandpool
synthesi
simpli
side
product
combinatori
chemistri
erlanson
final
aggreg
side
effect
high
concentr
assay
high
concentr
intermolecular
interact
compound
result
nonspecif
inhibit
target
protein
compound
might
high
affin
binder
erlanson
effect
document
past
studi
mani
compound
test
identifi
aggreg
babaoglu
et
al
pitfal
remain
intrins
caveat
small
molecul
librari
activitybas
small
molecul
screen
identifi
up
inhibitor
chen
dexheim
et
al
davydov
et
al
gombodorj
et
al
ott
et
al
pulvino
et
al
yang
et
al
yang
et
al
cumbersom
bottleneck
describ
prompt
use
approach
util
chemic
space
effect
way
erlanson
yuen
franzini
activitybas
screen
approach
small
molecul
screen
identifi
high
affin
binder
screen
small
molecul
ad
cell
cell
lysat
vitro
reaction
recombin
protein
test
inhibit
activ
target
protein
chang
phenotyp
detect
presenc
absenc
fluoresc
luminesc
janzen
commonli
use
screen
technolog
includ
imag
detect
bindingor
cleavagebas
excit
fluoresc
probelabel
protein
fluoresc
label
antibodi
target
specif
protein
fluoresc
reson
energi
transfer
fret
one
fluorophor
emit
energi
proxim
one
absorb
energi
excit
screen
also
conduct
use
flow
cytometri
measur
light
scatter
cell
determin
phenotyp
express
fluorescentlabel
protein
within
cell
luminescencebas
assay
similarli
design
fluoresc
imag
assay
mention
janzen
present
sever
repres
studi
util
screen
method
develop
chemic
compound
target
up
compon
differ
protein
famili
tabl
one
group
abl
identifi
two
molecul
fig
inhibit
activ
enzym
yang
et
al
ligas
yang
et
al
respect
first
screen
commerci
chemic
librari
confirm
lead
purchas
individu
compound
tabl
smallmolecul
librari
previous
develop
vousden
group
target
autoubiquitin
ligas
davydov
et
al
assay
small
molecul
incub
ubiquitin
reaction
recombin
ub
vitro
cellular
assay
gavori
et
al
odowd
et
al
electrochemiluminesc
ecm
label
antibodi
target
ubiquitin
protein
subsequ
ad
author
propos
reaction
significantli
reduc
ecm
repres
small
molecul
hit
inhibit
enzymat
activ
davydov
et
al
yang
et
al
yang
et
al
valid
hit
pyrazon
deriv
yang
et
al
found
target
enzym
inhibit
activ
ic
approxim
yang
et
al
compound
newli
identifi
famili
davydov
et
al
yang
et
al
shown
target
ligas
activ
ic
approxim
yang
et
al
knowledg
offtarget
effect
intracellular
efficaci
yet
thoroughli
assess
promiscu
natur
assay
detect
ubiquitin
protein
high
ic
valu
suggest
cellular
target
may
exist
anoth
pevonedistat
fig
tabl
adenosin
sulfam
mimet
chen
tsu
et
al
penovedistat
develop
medicin
chemistri
approach
aim
improv
previous
discov
inhibitor
adenosin
highthroughput
screen
souci
et
al
pevonedistat
origin
identifi
inhibitor
activ
activ
enzym
complex
souci
et
al
later
label
paninhibitor
activ
enzym
da
silva
et
al
gavin
et
al
wertz
wang
souci
et
al
report
potent
inhibit
singledigit
nanomolar
rang
crossreact
low
micromolar
rang
souci
et
al
pevonedistat
current
test
clinic
trial
patient
acut
myeloid
leukemia
princip
side
effect
seem
liver
toxic
sepsi
due
disrupt
gtpase
rhoa
cytoskeleton
protein
tumor
necrosi
factor
tnf
sword
et
al
sword
et
al
inhibitor
also
identifi
use
luciferas
report
cell
line
inhibitormedi
inactiv
target
protein
result
loss
luciferas
express
fig
tabl
studi
small
molecul
nitrofuran
inhibit
ub
conjug
enzym
complex
prevent
thioester
bond
format
ub
consequ
supress
activ
activ
bcell
lymphoma
cell
gombodorj
et
al
pulvino
et
al
fig
anoth
studi
also
identifi
inhibitor
neuroblastoma
cell
cheng
et
al
fig
shown
inhibit
concentr
hodg
et
al
anoth
group
develop
first
describ
fluorometr
cell
lysatebas
assay
mirror
physiolog
condit
small
molecul
screen
ott
et
al
target
dub
overexpress
mani
cancer
bishop
rocca
henley
proof
principl
develop
dub
inhibitor
cell
lysatebas
assay
call
alphalisa
ott
et
al
hatag
label
alphastreptavidin
donor
bead
probe
biotintag
ub
bind
ub
dub
would
result
fluoresc
convers
fluoresc
would
occur
presenc
inhibitor
ott
et
al
screen
yield
seri
compound
inhibit
dub
activ
rang
report
previous
includ
isogambon
acid
celastrol
mangiferin
rifampicin
ott
et
al
inhibitor
dub
implic
fanconi
anemia
signal
pathway
dna
damag
respons
bergink
jentsch
huang
et
al
nijman
et
al
identifi
smallmolecul
fluorometr
assay
employ
ub
substrat
modifi
rhodamin
chen
dexheim
et
al
emit
fluoresc
upon
cleavag
dang
melandri
stein
simpl
vitro
assay
could
use
highthroughput
fashion
screen
smallmolecul
inhibitor
previous
report
larger
inhibitor
dang
et
al
studi
identifi
novel
smallmolecul
compound
well
approv
drug
pimozid
diphenylbutylpiperidin
inhibitor
chen
dexheim
et
al
fig
tabl
nonsmal
cell
lung
carcinoma
cell
pimozid
shown
revers
chemoresist
observ
cisplatin
chen
dexheim
et
al
commonli
use
chemotherapi
drug
bloemink
reedijk
dasari
tchounwou
known
resist
fanconi
anemia
wang
interestingli
pimozid
antipsychot
drug
commonli
prescrib
patient
suffer
schizophrenia
seeman
although
postul
act
postsynapt
dopamin
receptor
blocker
mechan
remain
unknown
seeman
anoth
studi
confirm
pimozid
could
inhibit
turn
decreas
clonal
growth
glioblastoma
cell
well
increas
sensit
irradi
though
commonli
resist
chemotherapeut
irradi
treatment
lee
et
al
notwithstand
success
potenc
pimozid
ic
lower
clinic
approv
up
inhibitor
proteasom
inhibitor
bortezomib
ic
nm
fig
tabl
anoth
up
inhibitor
inhibit
dub
ic
nm
previous
studi
clinic
trial
termin
due
limit
toxic
studi
identifi
clinicaltrialsgov
wang
et
al
gener
activityand
targetbas
small
molecul
screen
provid
innov
approach
make
process
drug
discoveri
econom
effici
up
target
type
screen
yield
compound
suboptim
pharmacolog
properti
eg
biophys
solubl
cellular
permeabl
fall
short
term
potenc
specif
lill
wertz
postul
intrins
structur
catalyt
properti
up
protein
pose
impedi
gener
activesit
inhibitor
exampl
hect
contain
shallow
activ
site
subject
dynam
regul
includ
extrem
interdomain
rotat
accompani
catalysi
zheng
shabek
hand
conserv
natur
dub
catalyt
pocket
probabl
account
observ
low
specif
inhibitor
target
cystein
activ
site
inde
almost
up
small
molecul
inhibitor
current
clinic
clinic
trial
function
alloster
manner
instanc
nutlin
disrupt
substrat
bind
ligas
stabil
protein
level
transcript
activ
vassilev
et
al
smac
mimet
compet
caspas
bind
bir
domain
iap
inhibitor
apoptosi
protein
stimul
apoptosi
cancer
cell
liu
et
al
wu
et
al
final
proteasom
inhibitor
like
bortezomib
carfilzomib
one
famili
drug
thalidomidelenalidomid
target
up
compon
approv
treatment
cancer
specif
multipl
myeloma
bcell
neoplasm
thalidomid
well
known
advers
effect
fetu
develop
repurpos
cancer
therapi
bind
ligas
cereblon
crbn
stimul
lymphoid
transcript
factor
ubiquitin
degrad
ito
et
al
kronk
et
al
lu
et
al
therefor
develop
alloster
modul
up
compon
like
lead
effect
efficaci
cancer
therapeut
distinguish
fragmentbas
approach
smallmolecul
ht
assay
finetun
smallmolecul
screen
fragment
identifi
binder
target
protein
research
conduct
medicin
chemistri
grow
ligat
merg
fragment
potent
select
inhibitor
erlanson
lamore
hubbard
fig
approach
focu
activ
rather
discov
potenti
alloster
inhibitor
approach
detect
fragment
binder
environ
protein
might
activ
first
detect
whether
fragment
bind
target
protein
custom
fragment
via
medicin
chemistri
base
inform
gather
biophys
analys
eleg
exampl
fragmentbas
approach
use
develop
inhibitor
gavori
et
al
tabl
first
surfac
plasmon
reson
spr
use
screen
small
librari
molecul
target
catalyt
domain
respons
regul
domin
ub
ligas
gavori
et
al
iwakuma
lozano
distinguish
work
previou
studi
pioneer
first
inhibitor
kategaya
et
al
pozhidaeva
et
al
use
medicin
chemistri
tailor
initi
screen
hit
inhibitori
fragment
use
grow
six
differ
compound
retain
high
affin
origin
fragment
set
result
apart
poor
pharmacolog
properti
low
potenc
previous
obtain
kategaya
et
al
pozhidaeva
et
al
new
inhibitor
also
free
reactiv
speci
aggreg
importantli
work
identifi
new
alloster
inhibitori
site
impli
affinitybas
screen
rather
activitybas
screen
may
reveal
druggabl
site
anoth
group
also
use
similar
approach
develop
inhibitor
high
potenc
turnbul
et
al
work
exemplifi
two
studi
particularli
relev
produc
compound
activ
dub
method
proven
unsuccess
wrigley
et
al
research
develop
alloster
inhibitor
follow
studi
describ
detail
fragmentbas
medicin
chemistri
approach
identifi
novel
inhibitor
odowd
et
al
studi
demonstr
employ
spr
commonli
use
technolog
detect
bind
erlanson
first
use
identifi
potenti
alloster
binder
protein
continu
xray
crystallographi
enabl
structurebas
design
odowd
et
al
approach
respons
mani
drug
develop
date
erlanson
lamore
hubbard
studi
author
show
structurebas
design
aid
elucid
mechan
action
novel
inhibitor
provid
new
insight
function
complex
protein
addit
regulatori
site
beyond
activ
site
believ
import
implic
develop
inhibitor
dub
innov
decl
may
transform
hit
identif
alloster
binder
up
protein
faster
manag
process
thank
tag
molecul
oligonucleotid
ht
assay
mixtur
small
molecul
use
tradit
combinatori
chemistri
employ
disentangl
hit
usual
arduou
time
consum
howev
decl
technolog
inhibitor
lead
identifi
rapid
effici
method
includ
polymeras
chain
reaction
pcr
deep
dna
sequenc
mass
spectrometri
ensembl
therapeut
present
data
describ
use
decl
develop
macrocycl
compound
mullard
select
potent
inhibit
dodg
dub
associ
mani
cancer
murtaza
jolli
gecz
wood
howev
result
present
confer
proceed
without
inform
ultim
outcom
work
remain
unclear
nonetheless
predict
screen
employ
decl
inhibit
dub
up
target
decl
compris
combinatori
molecul
small
molecul
fragment
concaten
oligonucleotid
fig
mannocci
leimbach
wichert
scheuermann
neri
yuen
franzini
oligonucleotid
dna
peptid
nucleic
acid
pna
fig
greatest
advantag
dna
capac
amplif
though
amplifi
pna
advantag
dna
stabl
compat
solidphas
synthesi
pna
librari
also
amen
use
combinatori
chemistri
splitandpool
synthesi
method
zambaldo
barluenga
winssing
fig
report
decl
accommod
compound
goodnow
jr
et
al
hansen
group
describ
yoctolit
scale
dna
reactor
decreas
amount
materi
need
deepli
sampl
chemic
space
highli
effici
unbias
molecular
evolut
hansen
et
al
combinatori
chemistri
field
continu
produc
novel
strategi
gener
decl
costeffect
manner
decl
subject
process
describ
combinatori
chemistri
splitandpool
synthesi
also
suscept
pitfal
presenc
side
reaction
intermedi
byproduct
affect
interact
lead
fals
posit
gener
downstream
purif
librari
prior
use
ht
utmost
import
chemistri
appli
process
beyond
scope
review
review
elsewher
faval
bassi
scheuermann
neri
franzini
et
al
goodnow
jr
et
al
li
zheng
liu
li
decl
typic
made
singl
dual
pharmacophor
fig
singl
pharmacophor
synthes
dnarecord
dnatempl
method
dnarecord
method
compound
coupl
singlestrand
ss
doublestrand
ds
oligonucleotid
coupl
addit
dna
barcod
correspond
individu
compound
ligat
follow
amplif
gener
dsdna
dnatempl
method
involv
coupl
dnacompound
moieti
interact
via
barcod
complementar
close
proxim
coupl
linker
cleav
releas
compound
react
gener
cyclic
compound
link
dna
barcod
encod
selfassembl
chemic
esac
librari
also
known
dual
complex
pharmacophor
librari
initi
compound
coupl
ssdna
compound
coupl
spacer
use
hybrid
two
dnaencod
compound
follow
amplif
result
format
dual
pharmacophor
compound
coupl
dsdna
decl
costeffect
fragmentbas
librari
sinc
mani
methodolog
util
ht
decl
perform
bench
without
larg
dedic
equip
yuen
franzini
tag
target
protein
immobil
solid
support
follow
incub
decl
small
molecul
coupl
dna
pna
bind
target
enrich
via
tagspecif
methodolog
follow
elut
small
molecul
identifi
via
pcr
sequenc
case
dnaencod
librari
via
mass
spectrometri
spr
nmr
case
pnaencod
librari
mannocci
et
al
fig
amplif
also
carri
situ
yuen
franzini
regardless
particular
approach
inhibitor
develop
smallmolecul
ht
approach
depend
solubl
chemic
moieti
erlanson
prompt
use
phenotyp
screen
initi
screen
wagner
one
drive
forc
behind
field
peptidomimet
aim
util
favor
qualiti
peptid
includ
aqueou
solubl
membran
permeabl
intern
capac
maintain
abil
interact
protein
avoid
degrad
proteolysi
vagner
qu
hrubi
peptid
librari
also
gener
via
solidphas
synthesi
bessett
rice
daugherti
kenrick
daugherti
ryvkin
et
al
sidhu
coval
link
peptid
resin
conduct
synthesi
immobil
form
field
solidphas
peptid
synthesi
peptid
librari
typic
gener
use
bacteria
phage
display
exampl
antimicrobi
peptid
continu
identifi
screen
peptid
express
bacteria
tucker
et
al
one
studi
appli
phage
display
isol
potent
competit
peptid
bind
site
hect
ligas
inhibit
hect
ligas
oxid
activ
site
cystein
mund
lewi
maslen
pelham
phage
display
particular
like
decl
librari
fragment
har
screen
highaffin
bind
polypeptid
immobil
target
protein
highthroughput
manner
zhang
bendavid
sidhu
zhang
sidhu
major
obstacl
develop
small
molecul
inhibitor
up
compon
high
structur
similar
function
redund
among
protein
particular
famili
renatu
et
al
vandemark
hill
overcom
limit
knowledg
ub
pathway
phage
display
technolog
merg
produc
ub
variant
ubv
potent
highli
select
inhibitor
activ
up
enzym
ernst
et
al
ernst
sidhu
zhang
sartori
et
al
zhang
sidhu
ub
interact
weakli
specif
thousand
structur
similar
protein
via
common
bind
surfac
husnjak
dikic
intrins
conform
heterogen
lang
et
al
addit
ub
highli
stabl
protein
lack
cystein
residu
easili
produc
recombinantli
make
ideal
scaffold
gener
inhibitor
protein
up
job
et
al
via
protein
engin
sever
group
gener
ubv
remark
potenc
specif
cellular
activ
modul
enzymat
activ
up
protein
inde
given
pna
dna
fig
dnaencod
compound
librari
decl
approach
use
decl
drug
discoveri
similar
develop
combinatori
chemistri
splitandpool
synthesi
review
faval
et
al
franzini
et
al
goodnow
jr
et
al
compound
typic
develop
combinatori
synthesi
method
coupl
specif
dna
sequenc
pna
chain
b
schemat
represent
decl
decl
typic
begin
splitandpool
synthesi
assembl
differ
depend
whether
singl
pharmacophor
dnarecord
templat
dual
pharmacophor
encod
selfassembl
chemic
esac
dnarecord
involv
coupl
small
molecul
singlestrand
ss
doublestrand
ds
oligonucleotid
prior
ligat
dna
barcod
amplif
dnatempl
approach
involv
similar
process
dnarecord
time
alreadi
coupl
dnacompound
moieti
interact
via
complementar
proxim
linker
coupl
compound
dna
cleav
allow
compound
react
gener
cyclic
moieti
dual
pharmacophor
librari
consist
esac
librari
librari
like
dnarecord
compound
first
coupl
ssdna
hybrid
occur
thank
spacer
region
one
moieti
amplif
use
gener
dsdna
c
illustr
show
repres
screen
target
taggedprotein
immobil
tagbas
affin
method
allow
wash
impur
nonbind
enrich
hit
screen
conduct
via
amplif
mass
spectrometri
barcod
compound
dna
pna
respect
small
size
lack
disulfid
bond
structur
stabil
ub
repres
ideal
scaffold
next
gener
protein
therapeut
job
et
al
ubv
capabl
specif
inhibit
dub
vitro
vivo
mutat
residu
ub
core
surfac
research
genentech
develop
ubv
bound
tightli
inhibit
activ
cell
result
enhanc
ubiquitin
stabil
zhang
et
al
group
also
develop
inhibitor
ic
valu
low
nm
rang
employ
surfac
mutat
notabl
prove
potent
importantli
much
select
genentech
ubv
show
core
mutat
may
reduc
specif
thu
employ
great
care
inhibit
cancer
cell
consequ
caus
dramat
reduct
level
induct
apoptosi
synergi
cisplatin
suggest
ubv
could
use
enhanc
chemotherapeut
drug
w
zhang
sartori
et
al
also
develop
ubv
target
second
dub
deubiquitin
show
ubv
promot
export
nucleu
cytoplasm
zhang
sartori
et
al
recent
develop
ubv
four
ubbind
domain
engin
potent
bival
inhibitor
enzym
link
ubv
target
dusp
domain
ubv
target
catalyt
domain
teyra
et
al
fig
dimer
ubv
exhibit
enhanc
specif
inhibit
catalyt
activ
act
inhibitor
transform
growth
factor
signal
pathway
cell
teyra
et
al
also
util
ubv
reduc
abund
activ
cell
surfac
receptor
inhibit
enzym
regul
level
epiderm
growth
factor
receptor
egfr
receptor
fig
ernst
et
al
moreov
recent
establish
yeasttwohybrid
screen
platform
bruckner
polg
lentz
auerbach
schlattner
vivoselect
ubv
abl
inhibit
cellular
catalyt
activ
pasco
et
al
dub
involv
protect
prostat
cancer
apoptosi
priolo
et
al
extend
beyond
usp
dub
target
member
otu
dub
famili
ubv
bound
distal
activ
site
fig
nonetheless
potent
inhibit
diub
cleavag
ernst
et
al
past
also
employ
ubv
inhibitor
pathogen
dub
order
promot
infect
replic
host
cell
evad
immun
respons
mani
human
pathogen
virus
evolv
abil
hijack
manipul
up
luo
exampl
ubspecif
proteas
herp
simplex
viru
antagon
activ
wherea
oncoprotein
human
papillomaviru
recruit
host
ligas
promot
ubdepend
degrad
consequ
carcinogenesi
hoppeseyl
bossler
braun
herrmann
hoppeseyl
ye
su
xu
zheng
develop
highli
select
potent
ubv
target
dub
middl
east
respiratori
syndrom
coronaviru
merscov
crimeancongo
hemorrhag
fever
viru
cchfv
two
emerg
global
import
virus
w
zhang
baileyelkin
et
al
bound
subnanomolar
affin
merscov
dub
establish
wide
network
hydrophob
pack
hydrogen
bond
interact
fig
cellbas
assay
show
effici
suppress
dubinduc
activ
promot
therebi
provid
effici
blockad
viral
replic
reduc
merscov
progeni
titer
w
zhang
baileyelkin
et
al
moreov
han
et
al
recent
highlight
interplay
hect
ligas
matrix
protein
ebola
viru
promot
viral
bud
host
cell
han
et
al
therefor
ubbas
modul
up
may
enabl
gener
novel
antivir
drug
satur
mutagenesi
scan
experi
maynard
chen
georgiou
iverson
perform
distinct
ubv
target
structur
similar
catalyt
domain
enabl
elucid
interact
landscap
ub
usp
famili
leung
dekel
shifman
sidhu
pasco
et
al
thu
ubv
use
inhibitor
dub
also
model
molecul
identifi
altern
target
site
develop
smallmolecul
inhibitor
target
structur
conserv
protein
high
specif
hect
ligas
play
crucial
role
cancer
neurolog
disord
viral
infect
scheffner
kumar
contain
hect
domain
form
coval
bond
ub
catalyt
cystein
transfer
substrat
protein
understand
divers
hect
famili
limit
pauciti
select
potent
modul
despit
enorm
effort
develop
synthet
molecul
target
hect
hamper
larg
conform
chang
accompani
catalysi
shallow
activ
site
dynam
regul
activ
overcom
limit
systemat
develop
ubv
inhibitor
andor
activ
human
hect
zhang
et
al
structur
analysi
ubv
target
hect
ligas
reveal
ubv
inhibitor
act
block
bind
site
ligas
rather
block
activ
site
fig
zhang
et
al
demonstr
plastic
ub
fold
amen
develop
ubv
novel
biochem
properti
surprisingli
number
ubv
enhanc
catalyt
activ
hect
ligas
ernst
et
al
zhang
et
al
exampl
ubv
bound
tightli
select
increas
intracellular
ubiquitin
substrat
ernst
et
al
inhibit
migrat
cancer
cell
promot
ubiquitin
ra
homolog
gene
famili
member
b
rhob
zhang
et
al
ubv
also
modul
activ
membranebound
ion
channel
either
activ
inhibit
zhang
et
al
ubv
activ
inhibit
reduc
increas
cellsurfac
level
epitheli
sodium
channel
enac
respect
zhang
et
al
sinc
elev
enac
level
associ
hypertens
ronzaud
et
al
suppress
ion
channel
link
liddl
syndrom
novel
therapi
hypertens
could
develop
target
molecul
modul
enac
level
cell
surfac
aziz
memon
rahman
ali
member
ring
famili
account
human
ligas
contrast
hect
activ
catalyt
cystein
ring
domain
act
inert
scaffold
recruit
enzym
thioesterifi
ub
facilit
ub
transfer
substrat
due
lack
catalyt
cystein
inhibit
ring
function
challeng
identifi
ubv
target
ring
domain
ligas
cbl
ubvpcbl
reduc
intern
egfr
sustain
akt
pathway
activ
fig
gabrielsen
et
al
remark
ubvpcbl
bound
tightli
phosphoryl
cbl
pcbl
nonphosphoryl
cbl
demonstr
ubv
recogn
posttransl
modifi
protein
high
specif
gabrielsen
et
al
unexpectedli
also
isol
dimer
ubv
ubvxr
recogn
ring
domain
ligas
xiap
high
specif
stimul
ligas
activ
vitro
cell
gabrielsen
et
al
structur
ubvxr
complex
xiap
reveal
ubvxr
form
domainswap
dimer
stabil
conform
result
enhanc
activ
ligas
fig
gabrielsen
et
al
addit
util
ubv
technolog
target
ubbind
exosit
ring
domain
anaphasepromot
complex
subunit
brown
et
al
yamaguchi
et
al
probe
biochem
mechan
larg
cellcycl
regulatori
anaphasepromot
complex
apcc
sum
work
provid
gener
strategi
inhibit
activ
ring
ligas
modul
enzym
order
understand
catalyt
mechan
biolog
function
ubv
inhibitor
also
develop
member
multisubunit
scf
ligas
famili
shown
affect
mitot
cell
cycl
progress
cancer
cell
fig
gorelik
et
al
gorelik
et
al
structur
analysi
ubv
complex
target
reveal
extens
contact
fbox
show
ubv
inhibit
activ
block
bind
site
gorelik
et
al
structurebas
engin
loop
ubv
enabl
develop
specif
inhibitor
differ
member
scf
ligas
famili
gorelik
et
al
final
ubv
technolog
extend
target
noncatalyt
ubbind
domain
exemplifi
small
helic
ubinteract
motif
yeast
protein
fig
manczyk
et
al
engin
ubv
also
develop
target
protein
known
associ
ub
hoffmann
et
al
use
ribosom
display
zahnd
amstutz
pluckthun
develop
ubv
bound
inhibit
activ
tumor
necrosi
factor
alpha
hoffmann
et
al
similarli
recent
isol
ubv
bound
specif
human
epiderm
growth
factor
receptor
growth
factor
receptorbound
protein
show
ubv
act
potent
antagonist
cell
signal
leung
jarvik
sidhu
also
develop
potent
highli
select
ubv
inhibitor
tumor
suppressor
protein
recogn
ubiquitin
histon
act
central
regul
doublestrand
break
repair
pathway
fradetturcott
et
al
express
ubv
either
human
mous
cell
prevent
accumul
doublestrand
break
site
stimul
gene
convers
enhanc
effici
depend
gene
edit
canni
et
al
work
highlight
robust
protein
design
engin
ub
scaffold
potenti
target
dna
damag
signal
protein
applic
beyond
up
summari
ubv
technolog
repres
robust
platform
rapid
develop
intracellular
probe
target
discoveri
valid
deliveri
ubv
cell
repres
major
obstacl
direct
use
therapeut
constant
advanc
deliveri
technolog
fold
protein
capac
unlock
potenti
ubv
drug
candid
drug
discoveri
campaign
tradit
focu
develop
tight
specif
small
molecul
act
inhibitor
block
bind
pocket
activ
site
diseaseassoci
protein
although
approach
proven
success
salami
crew
limit
number
druggabl
protein
target
account
human
proteom
dixon
stockwel
landri
gie
raskandersen
almen
schioth
santo
et
al
uhlen
et
al
fact
nuclear
receptor
enzym
ion
channel
gproteincoupl
receptor
repres
major
current
drug
target
human
proteom
mainli
compos
protein
involv
organ
mainten
assemblydisassembl
protein
complex
regul
signal
transduct
event
critic
function
therefor
expand
druggabl
protein
space
research
employ
altern
approach
allow
target
transient
proteinprotein
interact
rather
deep
groov
small
molecul
bind
paradigm
shift
focus
use
small
molecul
control
cellular
level
drug
target
precis
degrad
rather
inhibit
activ
shift
target
inhibit
induc
target
destruct
exemplifi
proteolysistarget
chimera
protac
small
molecul
recruit
ubiquitin
ligas
protein
degrad
luca
ciulli
neklesa
winkler
crew
fact
protac
heterobifunct
molecul
compos
ligand
target
protein
fig
method
target
protein
degrad
represent
proteolysistarget
chimera
protac
technolog
protac
heterodimer
molecul
compos
proteintarget
warhead
connect
ub
ligas
binder
via
chemic
linker
protac
mediat
format
stabl
complex
target
protein
ligas
trigger
ubiquitin
proteosom
degrad
target
protein
b
clickform
proteolysi
target
chimera
cliptac
exploit
bioorthogon
click
reaction
transcyclooctenetag
binder
target
protein
tetrazinecontain
ub
ligas
binder
two
molecul
administ
individu
upon
cell
penetr
form
complet
protac
abl
induc
protein
degrad
c
ubiquitibodi
construct
fuse
scfv
chip
ub
ligas
scfv
enabl
specif
recognit
target
protein
ligas
facilit
ubiquitin
trigger
degrad
target
protein
fuse
halotag
achiev
hydrophob
protein
tag
via
sitespecif
coval
conjug
halotaggedadamantyl
moieti
england
luo
cai
adamantyl
moieti
display
target
protein
mimic
partial
unfold
state
protein
trigger
activ
cellular
qualiti
control
machineri
recruit
up
protein
degrad
e
hydrophob
tag
develop
modifi
inhibitor
target
protein
hydrophob
boc
arg
moieti
long
et
al
upon
bind
target
protein
modifi
inhibitor
enabl
recruit
proteasom
subsequ
degrad
warhead
ligand
ub
ligas
mediat
format
complex
drug
target
ligas
promot
ubiquitin
subsequ
degrad
target
fig
first
protac
built
link
target
protein
inhibitor
peptid
recruit
scf
ligas
sakamoto
et
al
although
protein
degrad
induc
rapid
deplet
target
methionin
estrogen
receptor
androgen
receptor
sakamoto
et
al
sakamoto
et
al
peptid
natur
ligas
engag
intrins
instabl
pose
limit
applic
technolog
breakthrough
protac
technolog
occur
use
nonpeptid
inhibitor
nutlin
engag
ligas
result
partial
degrad
androgen
receptor
cell
schneekloth
pucheault
tae
crew
howev
due
limit
activ
complex
chemic
composit
second
gener
protac
research
motiv
improv
stabil
pharmacokinet
properti
decreas
size
identifi
novel
ligas
recruit
buckley
et
al
effort
led
develop
current
protac
technolog
protac
reli
degrad
rather
inhibit
target
protein
show
remark
efficaci
dose
time
lower
convent
drug
bondeson
et
al
featur
potenti
reduc
system
toxic
vivo
recent
systemat
analysi
mode
action
protac
reveal
benefit
technolog
bondeson
et
al
studi
show
stabil
target
protac
ternari
complex
rather
affin
target
protac
interact
main
factor
respons
activ
bondeson
et
al
find
open
possibl
turn
low
affin
small
molecul
potent
protein
degrad
potenti
allow
rapid
develop
new
drug
comparison
degrad
activ
protac
differ
ligas
ligand
demonstr
ub
ligas
engag
dictat
efficaci
molecul
also
control
target
specif
bondeson
et
al
fact
protac
base
promiscu
kinas
inhibitor
bondeson
et
al
h
huang
et
al
render
select
simpli
engag
differ
ligas
suggest
specif
degrad
induc
protac
mainli
driven
endogen
ligand
specif
ligas
therefor
protac
hold
promis
develop
highli
specif
protein
degrad
even
use
nonspecif
warhead
target
protein
interest
thu
far
limit
number
ligas
exploit
gener
protac
technolog
advanc
develop
novel
ligand
recruit
ub
ligas
among
human
enzym
nakayama
nakayama
import
protac
compon
warhead
linker
engag
achiev
optim
target
degrad
describ
bondeson
et
al
lai
et
al
maniaci
et
al
zengerl
chan
ciulli
promin
role
play
linker
geometri
emerg
recent
burslem
et
al
gadd
et
al
exampl
short
linker
connect
promiscu
bromoand
extratermin
bet
ligand
potent
von
hippellindau
target
ligas
vhl
engag
allow
format
stabl
target
vhl
interfac
ensur
effici
specif
degrad
highli
homolog
protein
gadd
et
al
protac
offer
numer
advantag
convent
small
molecul
provid
opportun
expand
druggabl
protein
target
space
howev
number
question
remain
address
despit
modular
natur
protac
efficaci
specif
new
protac
need
assess
empir
chang
protac
chemic
composit
geometri
might
affect
activ
specif
therefor
develop
high
throughput
method
synthesi
character
protac
molecul
acceler
develop
new
inhibitor
limit
vivo
data
avail
qin
et
al
saenz
et
al
toxic
pharmacokinet
bioavail
tissu
distribut
metabol
protac
molecul
requir
extens
investig
larg
size
protac
da
might
affect
cell
permeabl
potenti
result
suboptim
present
target
ligas
smaller
protac
could
improv
cellular
uptak
potenc
overcom
obstacl
lebraud
et
al
develop
incel
clickform
proteolysi
target
chimera
cliptac
protac
form
intracellularli
upon
click
chemistrymedi
self
assembl
target
warhead
ligas
engag
lebraud
wright
johnson
heightman
fig
similar
protac
technolog
chimer
protein
form
singlechain
variabl
fragment
scfv
antibodi
fibronectin
type
iii
domain
monobodi
fuse
ub
ligas
carboxyl
terminu
protein
chip
also
use
degrad
target
protein
portnoff
stephen
varner
delisa
although
strategi
enabl
effici
deplet
target
protein
cell
applic
hinder
correct
fold
disulfid
bondcontain
scfv
reduc
environ
cell
cytoplasm
fig
anoth
method
trigger
select
protein
degrad
via
up
repres
modif
protein
hydrophob
tag
neklesa
crew
coval
modif
protein
hydrophob
tag
induc
recruit
molecular
chaperon
promot
ubiquitin
proteolyt
remov
target
proteasom
neklesa
et
al
fig
approach
achiev
select
deplet
reduc
cancer
cell
prolifer
xie
et
al
similarli
linkag
small
molecul
inhibitor
hydrophob
tertbutyl
carbamateprotect
arginin
boc
arg
moieti
induc
select
degrad
target
protein
long
gollap
hedstrom
fig
contrast
hydrophob
tag
boc
arg
moieti
enabl
effici
deplet
glutathion
stransferas
gst
bacteri
dihydrofol
reductas
dhfr
manner
independ
ub
atp
suggest
degrad
mediat
direct
interact
boc
arg
moieti
proteasom
subunit
long
et
al
without
requir
target
ubiquitin
recent
develop
demonstr
induc
protein
degrad
significantli
improv
recent
year
well
posit
expand
druggabl
protein
space
up
provid
wide
canva
develop
nextgener
cancer
therapeut
agent
advanc
ht
technolog
decreas
time
cost
need
carri
drug
discoveri
studi
activitybas
small
molecul
screen
yield
satisfi
number
viabl
drug
lead
recent
develop
fragmentbas
medicin
chemistri
methodolog
offer
promis
approach
tackl
small
moleculebas
screen
problem
advent
ubv
also
repres
excit
new
technolog
rapidli
provid
highli
potent
select
inhibitor
activ
enzym
resist
convent
approach
combin
fragmentbas
drug
discoveri
method
recent
develop
decl
small
molecul
screen
chemic
compound
displac
ubv
target
protein
could
enabl
deep
effect
sampl
chemic
space
modul
up
final
protac
technolog
repres
anoth
promis
mean
cancer
therapi
inde
seem
like
effect
cancer
therapi
futur
could
well
reli
combin
divers
innov
develop
druglik
entiti
activ
well
beyond
scope
current
drug
author
declar
conflict
interest
